SkylineDx Poster Presentations at ASH Meeting Further Validate Use of MMprofiler™ with SKY92 in Multiple Myeloma

SkylineDx Poster Presentations at ASH Meeting Further Validate Use of MMprofiler™ with SKY92 in Multiple Myeloma

PR Newswire

ROTTERDAM, the Netherlands and LAGUNA HILLS, California, Dec. 5, 2017

First Validation of SKY92 Prognostic Signature in Bortezomib-Thalidomide-Dexamethasone (VTD) Setting

Additional Data Yield Key Insights into Biology of Multiple Myeloma and Inform Design of Myeloma UK (MUK) Nine OPTIMUM Trial

ROTTERDAM, the Netherlands and LAGUNA HILLS, California, Dec. 5, 2017 /PRNewswire/ -- SkylineDx today announced the presentation of new data at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Atlanta, Georgia, that further validate the use of MMprofiler™ with SKY92, the company's prognostic tool to risk-stratify patients with multiple myeloma (MM).

The following MMprofiler™ with SKY92 datasets will be presented in ASH poster session 651: Myeloma – Biology and Pathophysiology, excluding Therapy: Poster III, at the Georgia World Congress Center, Building A, Level 1, Hall A2, on Monday, December 11, from 6-8pm ET:

In addition, the following dataset will be presented on Saturday, December 9, from 5:30-7:30pm ET, as part of ASH poster session 651: Myeloma – Biology and Pathophysiology, excluding Therapy: Poster I (also at the Georgia World Congress Center, Building A, Level 1, Hall A2):

"With proof of principle firmly established in numerous treatment settings, it is gratifying to have further validation of MMprofiler with SKY92 in the VTD setting, and to gain such important insights into signalling pathways in multiple myeloma," said Dharminder S. Chahal, Chief Executive Officer of SkylineDx. "With two datasets enhancing our understanding of the biology behind multiple myeloma, and with a third dataset informing the design of what promises to be a landmark trial, the ASH data presentations showcase how MMprofiler with SKY92 may ultimately inform therapeutic decision-making for patients living with this devastating disease."

For more information on MMprofiler™ with SKY92, including the three datasets presented at ASH, visit the SkylineDx booth (#2047) in the ASH Exhibit Hall at the Georgia World Congress Center Building B, Level 1, Halls B2-B4.

About Multiple Myeloma 
Multiple myeloma (MM) is a cancer that arises from plasma cells, a type of white blood cell made in the bone marrow. In patients with MM, the plasma cells become abnormal, multiply uncontrollably, and release only one type of antibody – known as M-protein – which has no useful function. According to the World Cancer Research Fund International, an estimated 114,000 people around the world are diagnosed with MM annually, and the disease represents 0.8% of all cancers globally.

For more information about MM, visit www.hematon.nl/myeloom (information available in Dutch only), www.themmrf.org, www.myeloma.org.uk, www.mpeurope.org, or www.myeloma.org.

About MMprofiler™ with SKY92
MMprofiler™ assesses risk by measuring the activity of 92 MM-related genes that comprise SKY92, SkylineDx's novel, prognostic gene classifier. The lead product of SkylineDx, MMprofiler™ is proven to be superior to the biomarkers currently used to risk-stratify newly diagnosed and relapsed multiple myeloma patients into a "high" or "standard" risk category.[1]  Included in a growing number of international treatment guidelines, MMprofiler™ is CE-IVD registered in Europe and will be coming soon as a laboratory-developed test (LDT) in the United States. For more information, please visit www.mmprofiler.com.   

About SkylineDx
SkylineDx is a commercial-stage biotech company based in Rotterdam, the Netherlands. Originally a spin-off of the Erasmus Medical Center in Rotterdam, the company specializes in the development and marketing of innovative gene signature-based prognostic tests to assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or to predict a patient's response to a specific treatment. Based on the test results, healthcare professionals can tailor the treatment to the individual patient. MMprofiler with SKY92 is the company's lead product. To learn more, please visit www.skylinedx.com.

Media Inquiries for SkylineDx
Jeffrey Jones, SkylineDx
949-303-8198
j.jones@skylinedx.com

Kara Golub
609-456-0822
kgolub@jfkhealth.com

 

[1] Van Beers EH, van Vliet M, de Best L, et al. SKY92 GEP, iFISH, and ISS comparisons for risk stratification in multiple myeloma. Poster p661 presented at 20th European Hematology Association Congress, Vienna, Austria, June 13, 2015.  

Voltar noticias em Inglês